# Placental Gene Expression Changes From Prenatal Cannabis Exposure Indicate Schizophrenia Risk > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/prenatal-cannabis-exposure-placental-gene-expression-schizophrenia-risk/ > **Published:** 2026-02-27T09:50:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:13:40-04:00 > **Clinical Summary:** Prenatal cannabis exposure placental gene expression changes may flag higher schizophrenia risk in offspring, highlighting neurodevelopmental impacts. --- ✦ New CED Clinical Relevance** #74 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyNeurologyPediatrics Why This Matters Pregnant patients who have used cannabis, even early in pregnancy, may want to discuss this emerging research with their obstetric and psychiatric care teams when considering their child’s long-term neurodevelopmental monitoring. Clinical Summary Emerging research suggests that prenatal cannabis exposure may produce measurable epigenetic and gene expression changes in placental tissue, particularly in pathways associated with neurodevelopmental risk including schizophrenia. The placenta, long underappreciated as a window into fetal programming, appears to reflect cannabis-related disruptions that could correlate with altered brain development trajectories in offspring. This line of investigation raises important questions about the biological mechanisms linking gestational [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) to psychiatric vulnerability later in life. Dr. Caplan’s Take “When placental tissue starts showing gene expression signatures linked to schizophrenia risk, the argument that prenatal cannabis is harmless because “it’s natural” becomes scientifically indefensible.” Clinical Perspective This research adds to growing evidence that prenatal cannabis exposure may have lasting effects on fetal neurodevelopment, particularly through placental mechanisms that influence gene expression related to [psychiatric risk](https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/). The potential link between placental changes and schizophrenia vulnerability underscores the importance of counseling patients of childbearing age about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during pregnancy, given the developing brain’s sensitivity to cannabinoid exposure. While this is preliminary research, it highlights the placenta as a useful biomarker tissue for understanding how prenatal cannabis may alter developmental trajectories, which could inform personalized [risk assessment](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/) in clinical settings. Clinicians should consider this evidence when discussing reproductive planning with cannabis-using patients and emphasize that pregnancy remains a period where abstinence is the most evidence-based approach. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Placental+Changes+From+Prenatal+%3Cb%3ECannabis%3C%2Fb%3E+Exposure+Could+Flag+Higher+Schizophrenia+...+%40drcaplan&url=https%3A%2F%2Fmedicaldaily.com%2Fplacental-changes-prenatal-cannabis-exposure-could-flag-higher-schizophrenia-risk-later-life-474843) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fmedicaldaily.com%2Fplacental-changes-prenatal-cannabis-exposure-could-flag-higher-schizophrenia-risk-later-life-474843) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Placental+Changes+From+Prenatal+%3Cb%3ECannabis%3C%2Fb%3E+Exposure+Could+Flag+Higher+Schizophrenia+...+%E2%80%94+via+%40drcaplan.bsky.social+https%3A%2F%2Fmedicaldaily.com%2Fplacental-changes-prenatal-cannabis-exposure-could-flag-higher-schizophrenia-risk-later-life-474843) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis** exposure](https://cedclinic.com/placental-genetic-markers-schizophrenia-risk-insights/) - [Can the placenta predict schizophrenia risk? Lessons from prenatal **cannabis** exposure](https://cedclinic.com/placental-genetic-markers-schizophrenia-risk-insights/) 📰 Source: [https://medicaldaily.com/placental-changes-prenatal-cannabis-exposure-could-flag-higher-schizophrenia-risk-later-life-474843](https://medicaldaily.com/placental-changes-prenatal-cannabis-exposure-could-flag-higher-schizophrenia-risk-later-life-474843) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Can the Placenta Predict Schizophrenia Risk? Lessons from Prenatal Cannabis Exposure](https://cedclinic.com/placental-genetic-markers-schizophrenia-risk-insights/) Explore how placental genetic markers may help predict schizophrenia risk linked to prenatal cannabis exposure. [Read More](https://cedclinic.com/placental-genetic-markers-schizophrenia-risk-insights/) [Brain Glutamate Changes Could Link Cannabis Use to a Higher Risk of Psychosis](https://cedclinic.com/brain-glutamate-changes-could-link-cannabis-use-to-a-higher-risk-of-psychosis/) Understand the neurochemical pathways that may connect cannabis use with increased [psychosis risk](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/). [Learn More](https://cedclinic.com/brain-glutamate-changes-could-link-cannabis-use-to-a-higher-risk-of-psychosis/) [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Stay updated on the latest [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) regarding cannabis effects on patient health outcomes. [Discover Insights](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).